|
1
|
Ferlay J, Colombet M, Soerjomataram I,
Mathers C, Parkin DM, Piñeros M, Znaor A and Bray F: Estimating the
global cancer incidence and mortality in 2018: GLOBOCAN sources and
methods. Int J Cancer. 144:1941–1953. 2019.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Parkin DM, Pisani P and Ferlay J: Global
Cancer Statistics. CA Cancer J Clin. 49:33–640. 1. 1999.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Li Y, Gu M, Jing F, Cai S, Bao C, Wang J,
Jin M and Chen K: Association between physical activity and all
cancer mortality: Dose-response meta-analysis of cohort studies.
Int J Cancer. 138:818–832. 2016.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Ye D, Jiang D, Zhang X and Mao Y: Alu
methylation and risk of cancer: A meta-analysis. Am J Med Sci.
359:271–280. 2020.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Arko-Boham B, Aryee NA, Blay RM, Owusu
EDA, Tagoe EA, Doris Shackie ES, Debrah AB and Adu-Aryee NA:
Circulating cell-free DNA integrity as a diagnostic and prognostic
marker for breast and prostate cancers. Cancer Genet.
235-236:65–71. 2019.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Pan Y, Liu G, Zhou F, Su B and Li Y: DNA
methylation profiles in cancer diagnosis and therapeutics. Clin Exp
Med. 18:1–14. 2018.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Schwarzenbach H, Hoon DS and Pantel K:
Cell-free nucleic acids as biomarkers in cancer patients. Nat Rev
Cancer. 11:426–437. 2011.PubMed/NCBI View
Article : Google Scholar
|
|
8
|
Shen J, Stass SA and Jiang F: MicroRNAs as
potential biomarkers in human solid tumors. Cancer Lett.
329:125–136. 2013.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Paterlini-Brechot P and Benali NL:
Circulating tumor cells (CTC) detection: Clinical impact and future
directions. Cancer Lett. 253:180–204. 2007.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Madhavan D, Wallwiener M, Bents K,
Zucknick M, Nees J, Schott S, Cuk K, Riethdorf S, Trumpp A, Pantel
K, et al: Plasma DNA integrity as a biomarker for primary and
metastatic breast cancer and potential marker for early diagnosis.
Breast Cancer Res Treat. 146:163–174. 2014.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Cuk K, Zucknick M, Heil J, Madhavan D,
Schott S, Turchinovich A, Arlt D, Rath M, Sohn C, Benner A, et al:
Circulating microRNAs in plasma as early detection markers for
breast cancer. Int J Cancer. 132:1602–1612. 2013.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Cuk K, Zucknick M, Madhavan D, Schott S,
Golatta M, Heil J, Marmé F, Turchinovich A, Sinn P, Sohn C, et al:
Plasma MicroRNA panel for minimally invasive detection of breast
cancer. PLoS One. 8(e76729)2013.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Madhavan D, Zucknick M, Wallwiener M, Cuk
K, Modugno C, Scharpff M, Schott S, Heil J, Turchinovich A, Yang R,
et al: Circulating miRNAs as surrogate markers for circulating
tumor cells and prognostic markers in metastatic breast cancer.
Clin Cancer Res. 18:5972–5982. 2012.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Tuchalska-Czuroń J, Lenart J, Augustyniak
J and Durlik M: Clinical value of tissue DNA integrity index in
pancreatic cancer. Surgeon. 18:269–279. 2020.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Chudasama DY, Aladag Z, Felicien MI, Hall
M, Beeson J, Asadi N, Gidron Y, Karteris E and Anikin VB:
Prognostic value of the DNA integrity index in patients with
malignant lung tumors. Oncotarget. 9:21281–21288. 2018.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Li M, Jia Y, Xu J, Cheng X and Xu C:
Assessment of the circulating cell-free DNA marker association with
diagnosis and prognostic prediction in patients with lymphoma: A
single-center experience. Ann Hematol. 96:1343–1351.
2017.PubMed/NCBI View Article : Google Scholar
|
|
17
|
El Messaoudi S, Mouliere F, Du Manoir S,
Bascoul-Mollevi C, Gillet B, Nouaille M, Fiess C, Crapez E, Bibeau
F, Theillet C, et al: Circulating DNA as a strong multimarker
prognostic tool for metastatic colorectal cancer patient management
care. Clin Cancer Res. 22:3067–3077. 2016.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Cheng J, Holland-Letz T, Wallwiener M,
Surowy H, Cuk K, Schott S, Trumpp A, Pantel K, Sohn C, Schneeweiss
A and Burwinkel B: Circulating free DNA integrity and concentration
as independent prognostic markers in metastatic breast cancer.
Breast Cancer Res Treat. 169:69–82. 2018.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Habeeb WH, Suleiman AA and Al-Hitawee HT:
Exploration of the beta-actin DNA integrity index as early genetic
marker of presence of breast cancer. Electron J Gen Med.
17(em188)2020.
|
|
20
|
Akca H, Demiray A, Yaren A, Bir F, Koseler
A, Iwakawa R, Bagci G and Yokota J: Utility of serum DNA and
pyrosequencing for the detection of EGFR mutations in non-small
cell lung cancer. Cancer Genet. 206:73–80. 2013.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Iqbal S, Vishnubhatla S, Raina V, Sharma
S, Gogia A, Deo SS, Mathur S and Shukla NK: Circulating cell-free
DNA and its integrity as a prognostic marker for breast cancer.
Springerplus. 4(265)2015.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Mandel P and Metais P: Nuclear Acids In
Human Blood Plasma. C R Seances Soc Biol Fil. 14:241–243.
1948.PubMed/NCBI(In French).
|
|
23
|
Tan EM, Schur PH, Carr RI and Kunkel HG:
Deoxybonucleic acid (DNA) and antibodies to DNA in the serum of
patients with systemic lupus erythematosus. J Clin Invest.
45:1732–1740. 1966.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Leon SA, Shapiro B, Sklaroff DM and Yaros
MJ: Free DNA in the serum of cancer patients and the effect of
therapy. Cancer Res. 37:646–650. 1977.PubMed/NCBI
|
|
25
|
Fleischhacker M and Schmidt B: Circulating
nucleic acids (CNAs) and cancer-A survey. Biochim Biophys Acta.
1775:181–232. 2007.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Jahr S, Hentze H, Englisch S, Hardt D,
Fackelmayer FO, Hesch RD and Knippers R: DNA fragments in the blood
plasma of cancer patients: Quantitations and evidence for their
origin from apoptotic and necrotic cells. Cancer Res. 61:1659–1665.
2001.PubMed/NCBI
|
|
27
|
Umetani N, Giuliano AE, Hiramatsu SH,
Amersi F, Nakagawa T, Martino S and Hoon DSB: Prediction of breast
tumor progression by integrity of free circulating DNA in serum. J
Clin Oncol. 24:4270–4276. 2006.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Diehl F, Li M, Dressman D, He Y, Shen D,
Szabo S, Diaz LA Jr, Goodman SN, David KA, Juhl H, et al: Detection
and quantification of mutations in the plasma of patients with
colorectal tumors. Proc Natl Acad Sci USA. 102:16368–16373.
2005.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Stamenkovic S, Cheng J, Surowy H,
Burwinkel B and Gündert M: Circulating cell-free DNA variables as
marker of ovarian cancer patients: A pilot study. Cancer Biomark.
28:159–167. 2020.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Hao TB, Shi W, Shen XJ, Shen XJ, Qi J, Wu
XH, Wu Y, Tang YY and Ju SQ: Circulating cell-free DNA in serum as
a biomarker for diagnosis and prognostic prediction of colorectal
cancer. Br J Cancer. 111:1482–1489. 2014.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Leng S, Zheng J, Jin Y, Zhang H, Zhu Y, Wu
J, Xu Y and Zhang P: Plasma cell-free DNA level and its integrity
as biomarkers to distinguish non-small cell lung cancer from
tuberculosis. Clin Chim Acta. 477:160–165. 2018.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Vizza E, Corrado G, De Angeli M, Carosi M,
Mancini E, Baiocco E, Chiofalo B, Patrizi L, Zampa A, Piaggio G and
Cicchillitti L: Serum DNA integrity index as a potential molecular
biomarker in endometrial cancer. J Exp Clin Cancer Res.
37(16)2018.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Thakur S, Tobey A, Daley B, Auh S, Walter
M, Patel D, Nilubol N, Kebebew E, Patel A, Jensen K, et al: Limited
utility of circulating cell-free dna integrity as a diagnostic tool
for differentiating between malignant and benign thyroid nodules
with indeterminate cytology (Bethesda Category III). Front Oncol.
9(905)2019.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Park MK, Lee JC, Lee JW and Hwang SJ: Alu
cell-free DNA concentration, Alu index, and LINE-1 hypomethylation
as a cancer predictor. Clin Biochem. 94:67–73. 2021.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Salem R, Ahmed R, Shaheen K, Abdalmegeed M
and Hassan H: DNA integrity index as a potential molecular
biomarker in colorectal cancer. Egypt J Med Hum Genet.
21(38)2020.
|
|
36
|
Lander ES, Linton LM, Birren B, Nusbaum C,
Zody MC, Baldwin J, Devon K, Dewar K, Doyle M, FitzHugh W, et al:
Initial sequencing and analysis of the human genome. Nature.
409:860–921. 2001.PubMed/NCBI View
Article : Google Scholar
|
|
37
|
Cheng J, Tang Q, Cao X and Burwinkel B:
Cell-free circulating DNA integrity based on peripheral blood as a
biomarker for diagnosis of cancer: A systematic review. Cancer
Epidemiol Biomarkers Prev. 26:1595–1602. 2017.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Umetani N, Kim J, Hiramatsu S, Reber HA,
Hines OJ, Bilchik AJ and Hoon DSB: Increased integrity of free
circulating DNA in sera of patients with colorectal or
periampullary cancer: Direct quantitative PCR for ALU repeats. Clin
Chem. 52:1062–1069. 2006.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Wang BG, Huang HY, Chen YC, Bristow RE,
Kassauei K, Cheng CC, Roden R, Sokoll LJ, Chan DW and Shih IeM:
Increased plasma DNA integrity in cancer patients. Cancer Res.
63:3966–3968. 2003.PubMed/NCBI
|
|
40
|
Holdenrieder S, Burges A, Reich O,
Spelsberg FW and Stieber P: DNA integrity in plasma and serum of
patients with malignant and benign diseases. Ann N Y Acad Sci.
1137:162–170. 2008.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Boddy JL, Gal S, Malone PR, Shaida N,
Wainscoat JS and Harris AL: The role of cell-free DNA size
distribution in the management of prostate cancer. Oncol Res.
16:35–41. 2006.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Schmidt B, Weickmann S, Witt C and
Fleischhacker M: Integrity of cell-free plasma DNA in patients with
lung cancer and nonmalignant lung disease. Ann N Y Acad Sci.
1137:207–213. 2008.PubMed/NCBI View Article : Google Scholar
|
|
43
|
Agostini M, Enzo MV, Bedin C, Belardinelli
V, Goldin E, Del Bianco P, Maschietto E, D'Angelo E, Izzi L,
Saccani A, et al: Circulating cell-free DNA: A promising marker of
regional lymphonode metastasis in breast cancer patients. Cancer
Biomark. 11:89–98. 2012.PubMed/NCBI View Article : Google Scholar
|
|
44
|
Lehner J, Stötzer OJ, Fersching D, Nagel D
and Holdenrieder S: Circulating plasma DNA and DNA integrity in
breast cancer patients undergoing neoadjuvant chemotherapy. Clin
Chim Acta. 425:206–211. 2013.PubMed/NCBI View Article : Google Scholar
|
|
45
|
Stötzer OJ, Lehner J, Fersching-Gierlich
D, Nagel D and Holdenrieder S: Diagnostic relevance of plasma DNA
and DNA integrity for breast cancer. Tumor Biol. 35:1183–1191.
2014.PubMed/NCBI View Article : Google Scholar
|
|
46
|
Cheng J, Cuk K, Heil J, Golatta M, Schott
S, Sohn C, Schneeweiss A, Burwinkel B and Surowy H: Cell-free
circulating DNA integrity is an independent predictor of impending
breast cancer recurrence. Oncotarget. 8:54537–54547.
2017.PubMed/NCBI View Article : Google Scholar
|
|
47
|
Hussein NA, Mohamed SN and Ahmed MA:
Plasma ALU-247, ALU-115, and cfDNA integrity as diagnostic and
prognostic biomarkers for breast cancer. Appl Biochem Biotechnol.
187:1028–1045. 2019.PubMed/NCBI View Article : Google Scholar
|
|
48
|
Feng J, Gang F, Li X, Jin T, Houbao H, Yu
C and Guorong L: Plasma cell-free DNA and its DNA integrity as
biomarker to distinguish prostate cancer from benign prostatic
hyperplasia in patients with increased serum prostate-specific
antigen. Int Urol Nephrol. 45:1023–1028. 2013.PubMed/NCBI View Article : Google Scholar
|
|
49
|
Fawzy A, Sweify KM, El-Fayoumy HM and
Nofal N: Quantitative analysis of plasma cell-free DNA and its DNA
integrity in patients with metastatic prostate cancer using ALU
sequence. J Egypt Natl Canc Inst. 28:235–242. 2016.PubMed/NCBI View Article : Google Scholar
|
|
50
|
Khani M, Hosseini J, Mirfakhraie R, Habibi
M, Azargashb E and Pouresmaeili F: The value of the plasma
circulating cell-free DNA concentration and integrity index as a
clinical tool for prostate cancer diagnosis: A prospective
case-control cohort study in an Iranian population. Cancer Manag
Res. 11:4549–4556. 2019.PubMed/NCBI View Article : Google Scholar
|
|
51
|
Zhang R, Pu W, Zhang S, Chen L, Zhu W,
Xiao L, Xing C and Li K: Clinical value of ALU concentration and
integrity index for the early diagnosis of ovarian cancer: A
retrospective cohort trial. PLoS One. 13(e0191756)2018.PubMed/NCBI View Article : Google Scholar
|
|
52
|
Tanaka H, Tsuda H, Nishimura S, Nomura H,
Kataoka F, Chiyoda T, Tanaka K, Iguchi Y, Susumu N and Aoki D: Role
of circulating free Alu DNA in endometrial cancer. Int J Gynecol
Cancer. 22:82–86. 2012.PubMed/NCBI View Article : Google Scholar
|
|
53
|
Waki K, Yokomizo K, Kawano K, Tsuda N,
Komatsu N and Yamada A: Integrity of plasma cell-free DNA as a
prognostic factor for vaccine therapy in patients with endometrial
cancer. Mol Clin Oncol. 14(29)2021.PubMed/NCBI View Article : Google Scholar
|
|
54
|
Sikora K, Bedin C, Vicentini C, Malpeli G,
D'Angelo E, Sperandio N, Lawlor RT, Bassi C, Tortora G, Nitti D, et
al: Evaluation of cell-free DNA as a biomarker for pancreatic
malignancies. Int J Biol Markers. 30:e136–e141. 2015.PubMed/NCBI View Article : Google Scholar
|
|
55
|
Utomo WK, Janmaat VT, Verhaar AP, Cros J,
Lévy P, Ruszniewski P, den Berg MS, Jenster G, Bruno MJ, Braat H,
et al: DNA integrity as biomarker in pancreatic cyst fluid. Am J
Cancer Res. 6:1837–1841. 2016.PubMed/NCBI
|
|
56
|
Mead R, Duku M, Bhandari P and Cree IA:
Circulating tumour markers can define patients with normal colons,
benign polyps, and cancers. Br J Cancer. 105:239–245.
2011.PubMed/NCBI View Article : Google Scholar
|
|
57
|
Leszinski G, Lehner J, Gezer U and
Holdenrieder S: Increased DNA integrity in colorectal cancer. In
Vivo. 28:299–303. 2014.PubMed/NCBI
|
|
58
|
El-Gayar D, El-Abd N, Hassan N and Ali R:
Increased free circulating DNA integrity index as a serum biomarker
in patients with colorectal carcinoma. Asian Pacific J Cancer Prev.
17:939–944. 2016.PubMed/NCBI View Article : Google Scholar
|
|
59
|
Bedin C, Enzo MV, Del Bianco P,
Pucciarelli S, Nitti D and Agostini M: Diagnostic and prognostic
role of cell-free DNA testing for colorectal cancer patients. Int J
Cancer. 140:1888–1898. 2017.PubMed/NCBI View Article : Google Scholar
|
|
60
|
Zhu F, Ma J, Ru D, Wu N, Zhang Y, Li H,
Liu X, Li J, Zhang H, Xu Y, et al: Plasma DNA Integrity as a
prognostic biomarker for colorectal cancer chemotherapy. J Oncol.
2021(5569783)2021.PubMed/NCBI View Article : Google Scholar
|
|
61
|
Soliman SES, Alhanafy AM, Habib MSE, Hagag
M and Ibrahem RAL: Serum circulating cell free DNA as potential
diagnostic and prognostic biomarker in non small cell lung cancer.
Biochem Biophys Rep. 15:45–51. 2018.PubMed/NCBI View Article : Google Scholar
|
|
62
|
Waki K, Yokomizo K, Yoshiyama K, Takamori
S, Komatsu N and Yamada A: Integrity of circulating cell-free DNA
as a prognostic biomarker for vaccine therapy in patients with
nonsmall cell lung cancer. Immunopharmacol Immunotoxicol.
43:176–182. 2021.PubMed/NCBI View Article : Google Scholar
|
|
63
|
Ren S, Ren X, Guo H, Liang L, Wei K, Guo
L, Qu X, Dai X and Huang Q: Concentration and integrity indexes of
urine cell-free DNA as promising biomarkers for early lung cancer
diagnosis. Per Med. 18:129–139. 2021.PubMed/NCBI View Article : Google Scholar
|
|
64
|
Jiang P, Chan CW, Chan KC, Cheng SH, Wong
J, Wong VW, Wong GL, Chan SL, Mok TS, Chan HL, et al: Lengthening
and shortening of plasma DNA in hepatocellular carcinoma patients.
Proc Natl Acad Sci USA. 112:E1317–E1325. 2015.PubMed/NCBI View Article : Google Scholar
|
